Effects Of The Drugs And Interventions, Used For The Management Of Cancer Treatment-Related Oral Mucositis, On The Induced Oral Pain.

10.5580/2c2b ◽  
2012 ◽  
Vol 9 (1) ◽  
Keyword(s):  
Cancer Treatment ◽  
Oral Mucositis ◽  
Oral Pain

scholarly journals Methylene Blue for the Treatment of Intractable Pain From Oral Mucositis Related to Cancer Treatment: An Uncontrolled Cohort

2021 ◽  
Vol 19 (5) ◽  
pp. 521-527
Author(s):  
Carlos J. Roldan ◽  
Matthew Chung ◽  
Lei Feng ◽  
Eduardo Bruera
Keyword(s):  
Methylene Blue ◽  
Cancer Treatment ◽  
Oral Mucositis ◽  
Cancer Type ◽  
Duration Of Symptoms ◽  
Safe Treatment ◽  
Oral Rinse ◽  
Refractory Pain ◽  
Pain Scores ◽  
Oral Pain

Background: Oral mucositis is a complication of cancer therapy, causing severe pain that affects oral functioning, nutrition, and quality of life, as well as therapy nonadherence or dose-limiting toxicity. Anecdotal experience has suggested that methylene blue (MB) oral rinse may be an effective and safe treatment of this oral pain. Methods: To evaluate the efficacy and safety of MB oral rinse for the treatment of oral pain due to mucositis in patients with cancer, we retrospectively evaluated patients who experienced refractory pain despite conventional therapy. Results: We identified 281 patients who received MB oral rinse. Most were receiving treatment for leukemia (n=85; 30.3%) and head and neck squamous cell carcinoma (n=84; 29.9%). The most common treatments were radiation therapy alone (n=108; 38.4%) and chemoradiation (n=86; 30.6%). Median duration of symptoms was 14 days. Mean (SD) numeric rating scale pain scores were 7.7 (1.83; median, 8) before MB oral rinse and 2.51 (2.76; median, 2) after MB oral rinse (P<.0001). Most patients achieved pain control within the first 3 doses. The effectiveness of MB oral rinse was independent of patient age, sex, cancer type, cancer stage, MB dilution, and pain duration or baseline pain scores. The lowest response to treatment was reported in individuals with esophageal mucositis. Few patients experienced adverse effects of MB oral rinse (n=13; 4.6%); 10 had a transient burning sensation, 2 had transient blue discoloration of the teeth and mouth, and 1 had increased pain. Conclusions: MB oral rinse is an effective and safe treatment for refractory pain from oral mucositis related to cancer treatment.

scholarly journals Incidence of Oral Mucositis in Patients Undergoing Head and Neck Cancer Treatment: Systematic Review and Meta-Analysis

2021 ◽  
Vol 5 (1) ◽  
pp. 23
Author(s):  
Raquel Pacheco ◽  
Maria Alzira Cavacas ◽  
Paulo Mascarenhas ◽  
Pedro Oliveira ◽  
Carlos Zagalo
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Oral Health ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Oral Mucositis ◽  
Negative Impact ◽  
Meta Analysis ◽  
Incidence Rates

This systematic review and meta-analysis aimed to assess the literature about the incidence of oral mucositis and its degrees (mild, moderate, and severe), in patients undergoing head and neck cancer treatment (radiotherapy, chemotherapy, and surgery). Addressing this issue is important since oral mucositis has a negative impact on oral health and significantly deteriorates the quality of life. Therefore, a multidisciplinary team, including dentists, should be involved in the treatment. The overall oral mucositis incidence was 89.4%. The global incidence for mild, moderate, and severe degrees were 16.8%, 34.5%, and 26.4%, respectively. The high incidence rates reported in this review point out the need for greater care in terms of the oral health of these patients.

Predicting discrepancy between pain report and observed tissue damage during oral mucositis following cancer treatment

Pain ◽  
1990 ◽  
Vol 41 ◽  
pp. S366
Author(s):  
M.W. Davis ◽  
B.E. Williams ◽  
K.L. Syrjala ◽  
G.W. Donaldson
Keyword(s):  
Cancer Treatment ◽  
Oral Mucositis ◽  
Tissue Damage ◽  
Pain Report

Methotrexate-induced oral mucositis in rheumatoid arthritis disease: Therapeutic strategy in a case report/Methotrexat-induzierte orale Mukositis bei rheumatoider Arthritis: Therapeutische Strategie in einem Fallbericht

2013 ◽  
Vol 2 (1) ◽  
Author(s):  
Margherita Gobbo ◽  
Giulia Ottaviani ◽  
Rossana Bussani ◽  
Gabriele Pozzato ◽  
Matteo Biasotto
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Oral Cavity ◽  
Oral Mucositis ◽  
Low Level Laser Therapy ◽  
Rheumatoid Arthritis Disease ◽  
Oral Pain ◽  
Relieve Pain ◽  
Level Laser

AbstractThe aim of this case report is to evaluate the efficacy of low-level laser therapy (LLLT) in the treatment of oral mucositis induced by methotrexate (MTX).A 52-year-old male patient, affected by rheumatoid arthritis and treated with corticosteroids and MTX, complained about severe oral pain and lesions for two months. He had been treated with topical and systemic corticosteroid therapy and chlorhexidine rinses with no significant improvement. He was not able to eat solid food or to wear his dental prosthesis. Examination of the oral cavity revealed retro-commissural and labial bilateral ulcerations and erythema and a 2-cm wide fibrous white lesion on the lower anterior vestibular ridge. Blood tests showed mild pancytopenia, and oral biopsies evidenced a “non-specific inflammatory condition” excluding any precancerous or paraneoplastic lesion or autoimmune diseases of the oral cavity. Previous medical records revealed that MTX had been discontinued many times due to mucositis since 2006, when the therapy had been started. This suggested a correlation between the onset of oral mucositis and MTX accumulation. LLLT was carried out for 4 consecutive days and three once-a-week follow-ups were performed.Lesions had completely healed during the second follow-up and the patient referred no pain at all from the 4th laser session on, therefore, the discontinuation of MTX had not been necessary.LLLT could represent an innovative technique to relieve pain related to MTX side effects thus avoiding dangerous discontinuation of therapy.

Development of a buccal doxepin platform for pain in oral mucositis derived from head and neck cancer treatment

2017 ◽  
Vol 117 ◽  
pp. 203-211 ◽  
Author(s):  
Roser Sanz ◽  
Ana C. Calpena ◽  
Mireia Mallandrich ◽  
Álvaro Gimeno ◽  
Lyda Halbaut ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Oral Mucositis

scholarly journals Efficacy of Traditional Chinese Medicine in Treatment and Prophylaxis of Radiation-Induced Oral Mucositis in Patients Receiving Radiotherapy: A Randomized Controlled Trial

2017 ◽  
Vol 17 (2) ◽  
pp. 444-450 ◽  
Author(s):  
Cong Wang ◽  
Peiguo Wang ◽  
Huaqiang Ouyang ◽  
Jing Wang ◽  
Lining Sun ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Chinese Medicine ◽  
Treatment Group ◽  
Traditional Chinese Medicine ◽  
Body Mass ◽  
Oral Mucositis ◽  
Visual Analysis ◽  
Control Group ◽  
Oral Pain ◽  
Radiation Induced

Objective: To estimate the efficacy of traditional Chinese medicine (Chining decoction, CHIN) for radiation-induced oral mucositis in patients with head and neck cancer. Methods: From May 2014 to December 2015, 70 consecutive patients were randomly assigned to receive CHIN (treatment group) or recombinant human epidermal growth factor (rhEGF) spray (control group) at a 1:1 ratio. CHIN was administered to treatment group from the first day of radiotherapy until the completion of radiotherapy. Simultaneously, the rhEGF spray was administered to control group on the oral mucosa of irradiated area. The clinical benefit was determined by gradation of mucositis (Common Terminology Criteria for Adverse Events v4.0), oral pain, and xerostomia (visual analysis scale) for each week during radiotherapy. Body mass index was evaluated before and after radiotherapy. Results: Patients in the treatment group had prominent remission of oral pain and grade of mucositis on each observing point compared with those in control group ( P < .01). Xerostomia was decreased notably in treatment group compared with control group ( P < .01). Body mass index in the treatment group exhibited advantage over control group after radiotherapy, but there was no statistical significance (19.8 ± 3.26 vs 18.8 ± 2.5 kg/m2, P = .153, >.05). Conclusions: CHIN presented an obvious advantage in preventing radiation-induced oral mucositis compared with rhEGF spray.

Skin and mucosal alterations

2007 ◽  
pp. 635-652
Keyword(s):  
Body Image ◽  
Cancer Treatment ◽  
Advanced Cancer ◽  
Oral Mucositis ◽  
Hair Loss ◽  
Side Effect ◽  
Oral Care ◽  
Scalp Cooling ◽  
It Impacts ◽  
Scalp Hypothermia

Hair loss (alopecia) 636 Scalp cooling (scalp hypothermia) 638 Oral mucositis and related problems 640 Oral mucositis: managing the process and symptoms 644 Oesophagitis 646 Oral care in advanced cancer 647 Malignant wounds 648 Lymphoedema 650 Hair loss can be a distressing side effect of cancer treatment; it impacts on body image and feelings of attractiveness, creates anxiety and causes a visual reminder of the disease and treatment. Alopecia is not a major side effect for most people, but a small group of patients will become extremely distressed by it....

Oral Cryotherapy for Preventing Oral Mucositis in Patients Receiving Cancer Treatment

JAMA Oncology ◽  
2016 ◽  
Vol 2 (10) ◽  
pp. 1365 ◽  
Author(s):  
Philip Riley ◽  
Martin G. McCabe ◽  
Anne-Marie Glenny
Keyword(s):  
Cancer Treatment ◽  
Oral Mucositis ◽  
Oral Cryotherapy

scholarly journals Effect ofKangfuxinSolution on Chemo/Radiotherapy-Induced Mucositis in Nasopharyngeal Carcinoma Patients: A Multicenter, Prospective Randomized Phase III Clinical Study

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Yangkun Luo ◽  
Mei Feng ◽  
Zixuan Fan ◽  
Xiaodong Zhu ◽  
Feng Jin ◽  
...  
Keyword(s):  
Clinical Study ◽  
Nasopharyngeal Carcinoma ◽  
Adverse Events ◽  
Oral Mucositis ◽  
Rating Scale ◽  
Test Group ◽  
Phase Iii ◽  
Control Group ◽  
Oral Pain ◽  
Gastrointestinal Mucositis

Objective. To evaluate the efficacy and safety ofKangfuxinSolution, a pure Chinese herbal medicine, on mucositis induced by chemoradiotherapy in nasopharyngeal carcinoma patients.Methods. A randomized, parallel-group, multicenter clinical study was performed. A total of 240 patients were randomized to receive eitherKangfuxinSolution (test group) or compound borax gargle (control group) during chemoradiotherapy. Oral mucositis, upper gastrointestinal mucositis, and oral pain were evaluated by Common Terminology Criteria for Adverse Events (CTCAE) v3.0 and the Verbal Rating Scale (VRS).Results. Of 240 patients enrolled, 215 were eligible for efficacy analysis. Compared with the control group, the incidence and severity of oral mucositis in the test group were significantly reduced (P=0.01). The time to different grade of oral mucositis occurrence (grade 1, 2, or 3) was longer in test group (P<0.01), and the accumulated radiation dose was also higher in test group comparing to the control group (P<0.05). The test group showed lower incidence of oral pain and gastrointestinal mucositis than the control group (P<0.01). No significant adverse events were observed.Conclusion.KangfuxinSolution demonstrated its superiority to compound borax gargle on mucositis induced by chemoradiotherapy. Its safety is acceptable for clinical application.

Sign in / Sign up

Export Citation Format

Share Document